title: Thyroid carcinoma with tracheal or esophageal involvement: limited or maximal surgery?
abstract: This retrospective study was undertaken to evaluate the prognosis of and to determine optimal therapy for thyroid carcinoma adhering to or invading the trachea or esophagus. In our series of 412 operated thyroid cancers, there were 45 patients including 20 with adherences to the trachea or esophagus that were dissected free by sharp dissection (group 1), six patients with invasion of the trachea or esophagus who underwent total resection followed by radioiodine and external-beam irradiation (group 2), and 19 patients with invasion of the trachea or esophagus that had been incompletely resected (group 3). There were no major complications. Survival or disease-free unrelated deaths were recorded in 80%, 100%, and 16% of patients in groups 1, 2, and 3, respectively. The three patients with anaplastic carcinoma in group 1 are free of disease 3, 6, and 7 years after operation, respectively. Combined with those in the literature, our data indicate that (1) adherences to the trachea or esophagus are not necessarily associated with poor prognosis and should be treated with aggressive surgery even in anaplastic carcinoma, (2) invasion of the trachea or esophagus must be treated whenever possible by total resection followed by radioiodine and external-beam irradiation, (3) a two-stage operation should be considered when optimal conditions are not available initially, and (4) cure may be obtained with complementary radioiodine and external-beam irradiation after incomplete resection of papillary carcinoma.
authors.affiliation: CHU Henri Mondor, Créteil, France.
authors.forename: D J
authors.initials: DJ
authors.lastname: Mellière
authors.forename: N E
authors.initials: NE
authors.lastname: Ben Yahia
authors.forename: J P
authors.initials: JP
authors.lastname: Becquemin
authors.forename: F
authors.initials: F
authors.lastname: Lange
authors.forename: H
authors.initials: H
authors.lastname: Boulahdour
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002277:Carcinoma / Q000401:mortality / Q000532:radiotherapy / Q000556:secondary / Q000601:surgery*; D002291:Carcinoma, Papillary / Q000401:mortality / Q000556:secondary / Q000601:surgery; D002648:Child; D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000601:surgery; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D013964:Thyroid Neoplasms / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery*; D014134:Tracheal Neoplasms / Q000532:radiotherapy / Q000556:secondary* / Q000601:surgery*